Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer
Age between 18 and 75 years;
Pathological diagnosis of high-grade serous ovarian cancer;
Newly diagnosed ovarian cancer case without prior neoadjuvant therapy.
Non-primary (recurrent) patients;
Ovarian cancer patients who have not undergone surgical treatment;
Patients with a history of other malignancies.